640 related articles for article (PubMed ID: 25060672)
1. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
[TBL] [Abstract][Full Text] [Related]
3. Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer.
Getzler I; Bahouth Z; Nativ O; Rubinstein J; Halachmi S
BMC Urol; 2018 Oct; 18(1):90. PubMed ID: 30348146
[TBL] [Abstract][Full Text] [Related]
4. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
[TBL] [Abstract][Full Text] [Related]
5. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
[TBL] [Abstract][Full Text] [Related]
6. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
Vartolomei MD; Ferro M; Cantiello F; Lucarelli G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdona S; Verze P; La Rocca R; Borghesi M; Schiavina R; Brunocilla E; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Serretta V; Russo GI; Morgia G; Terracciano D; Musi G; de Cobelli O; Mirone V; Shariat SF
Clin Genitourin Cancer; 2018 Dec; 16(6):445-452. PubMed ID: 30077463
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study.
Favilla V; Castelli T; Urzì D; Reale G; Privitera S; Salici A; Russo GI; Cimino S; Morgia G
Int Braz J Urol; 2016; 42(4):685-93. PubMed ID: 27564278
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
Vartolomei MD; Porav-Hodade D; Ferro M; Mathieu R; Abufaraj M; Foerster B; Kimura S; Shariat SF
Urol Oncol; 2018 Sep; 36(9):389-399. PubMed ID: 29884342
[TBL] [Abstract][Full Text] [Related]
9. Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer?
Albayrak S; Zengin K; Tanik S; Atar M; Unal SH; Imamoglu MA; Gurdal M
Kaohsiung J Med Sci; 2016 Jun; 32(6):327-33. PubMed ID: 27377847
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer.
D'Andrea D; Moschini M; Gust K; Abufaraj M; Özsoy M; Mathieu R; Soria F; Briganti A; Rouprêt M; Karakiewicz PI; Shariat SF
Clin Genitourin Cancer; 2017 Oct; 15(5):e755-e764. PubMed ID: 28420564
[TBL] [Abstract][Full Text] [Related]
11. The Preoperative Neutrophil-to-lymphocyte Ratio is a Novel Biomarker for Predicting Worse Clinical Outcomes in Non-muscle Invasive Bladder Cancer Patients with a Previous History of Smoking.
Ogihara K; Kikuchi E; Yuge K; Yanai Y; Matsumoto K; Miyajima A; Asakura H; Oya M
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):1039-1047. PubMed ID: 27660257
[TBL] [Abstract][Full Text] [Related]
12. Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
Int Braz J Urol; 2019; 45(2):315-324. PubMed ID: 30785697
[TBL] [Abstract][Full Text] [Related]
13. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
Cantiello F; Russo GI; Vartolomei MD; Farhan ARA; Terracciano D; Musi G; Lucarelli G; Di Stasi SM; Hurle R; Serretta V; Busetto GM; Scafuro C; Perdonà S; Borghesi M; Schiavina R; Cioffi A; De Berardinis E; Almeida GL; Bove P; Lima E; Ucciero G; Matei DV; Crisan N; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Mirone V; Shariat SF; Ferro M
Eur Urol Oncol; 2018 Oct; 1(5):403-410. PubMed ID: 31158079
[TBL] [Abstract][Full Text] [Related]
14. Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study.
Ziani I; Ibrahimi A; Zaoui Y; El Sayegh H; Abouqal R; Nouini Y; Bouziane A
Pan Afr Med J; 2023; 44():145. PubMed ID: 37396698
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy.
Morizawa Y; Miyake M; Shimada K; Hori S; Tatsumi Y; Nakai Y; Anai S; Tanaka N; Konishi N; Fujimoto K
Urol Oncol; 2016 Jun; 34(6):257.e11-7. PubMed ID: 27038696
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
17. A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy.
Tanaka N; Kikuchi E; Kanao K; Matsumoto K; Shirotake S; Miyazaki Y; Kobayashi H; Kaneko G; Hagiwara M; Ide H; Obata J; Hoshino K; Hayakawa N; Kosaka T; Hara S; Oyama M; Momma T; Nakajima Y; Jinzaki M; Oya M
Ann Surg Oncol; 2014 Nov; 21(12):4041-8. PubMed ID: 24912614
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma.
Lee SM; Russell A; Hellawell G
Korean J Urol; 2015 Nov; 56(11):749-55. PubMed ID: 26568792
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of prognosis using the neutrophil-lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
BJU Int; 2015 Apr; 115(4):587-94. PubMed ID: 24947340
[TBL] [Abstract][Full Text] [Related]
20. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.
Fang D; Zhang L; Li X; Yu W; Singla N; Zhao G; Xiong G; Song Y; He Q; He Z; Zhou L
Ann Surg Oncol; 2015 Aug; 22(8):2789-98. PubMed ID: 25564161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
